Detect vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Detect pioneered the FDA-authorized rapid at-home molecular COVID-19 test and is now developing a second-gen molecular diagnostics platform targeting STIs and respiratory infections with 15-minute results.
About
Detect Inc. is a molecular diagnostics company that commercialized one of the first FDA-authorized rapid at-home molecular COVID-19 tests, bringing lab-quality PCR-equivalent results to consumers at home for the first time during the 2021-22 Omicron surge. The company''s proprietary molecular testing platform integrates a reader device and single-use cartridge that performs nucleic acid amplification testing (NAAT) — the gold standard for infectious disease diagnosis — outside of a clinical laboratory setting.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.